Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lung cancer key for Takeda's alisertib after Ph III lymphoma flop

This article was originally published in Scrip

Executive Summary

Takeda's hopes for its first-in-class Aurora kinase inhibitor now rest on Phase II studies in lung cancer after the company pulled the plug on its Phase III trial in a rare form of lymphoma.

You may also be interested in...



Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates

Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.

Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m

Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.

Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks

COVID-19 products contributed almost a third to the global revenues from the top 20 best-selling drugs in 2022. However, strong growth was also seen for drugs across categories from immunology and cancer to HIV and cardiometabolic.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC028705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel